Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions

That is the title of my new paper in Annals of the American Thoracic Society with co-authors David Ost, Fabien Maldonado, Jaehong Kim , Moises Marin, Tony Amos, Deanna Hertz, Iftekhar Kalsekar, and Anil Vachani. The abstract is below. Rational: While previous studies have assessed the clinical or economic value of specific technologies, the economic…

Meet me at ISPOR 2022

I’ll be attending ISPOR 2022 in Washington DC next week. It’ll be great to see a number of my peers in person after two years of virtual meetings. One of my research papers that will be presented is titled “Economic Impact of Sequential Testing for COVID-19 and Influenza with Molecular Point of Care in 3…

HTA criteria used to evaluate diagnostics

When evaluating a new diagnostic, HTA agencies must assess two separate issues: analytical and clinical validity. Analytical validity basically indicates whether the test works; is it able to accurately predicts the presence or absence of a particular biomarker of interest. Clinical validity is whether the test matters in clinical practice.  It could be the case…

Patient care under uncertainty: Or why I learned to stop loving clinical practice guidelines

The National Cancer Institute defines personalized medicine as “uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease”. In practice, however, patient treatment is rarely personalized by individual since evidence to support complete personalization is rarely available. Personalization in practice more often means care that varies with some individual characteristics.…